Follicular Lymphoma
Conference Coverage
Ibrutinib/buparlisib looks good for relapsed mantle cell lymphoma
LUGANO, SWITZERLAND – The overall response rate among patients with mantle cell lymphoma in a phase I/IB dose escalation study was 100%,...
Conference Coverage
Pembrolizumab + rituximab boost response rates in relapsed follicular lymphoma
LUGANO, SWITZERLAND – The overall response rate with the combination was 65%, including 50% complete responses, in 20 patients with relapsed...
Conference Coverage
CARs race for supremacy against aggressive non-Hodgkin lymphoma
MADRID - Two chimeric antigen receptor T cell (CAR-T) constructs are showing promising activity against treatment-refractory, aggressive forms of...
News
New SC rituximab formulation approved, reduces administration time
The US Food and Drug Administration (FDA) approved a new, subcutaneous (SC) formulation of rituximab with hyaluronidase human (Rituxan Hycela™)....
Conference Coverage
Twofer drug blocks SYK/JAK pathways in advanced NHL
MADRID – Cerdulatinib is an orally dosed agent that inhibits both the Janus kinase (JAK) 1 and 3 pathways and the spleen tyrosine kinase (SYK)...
Conference Coverage
Chemo-free triplet produces ‘favorable’ results in advanced disease
LUGANO, SWITZERLAND—A chemotherapy-free combination regimen has demonstrated “favorable” safety and efficacy in patients with advanced chronic...
News
FDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLL
Approval provides patients a subcutaneous route for rituximab, significantly reducing the administration time.
Conference Coverage
Inhibitor elicits responses in heavily pretreated FL, DLBCL
LUGANO, SWITZERLAND—Interim results of a phase 2 trial suggest tazemetostat can be effective in patients with heavily pretreated, relapsed or...
Conference Coverage
Lenalidomide-rituximab induces high CR rate in untreated follicular lymphoma
LUGANO, SWITZERLAND – The combination “can be a highly effective and reasonably well-tolerated treatment approach for patients with untreated...
Conference Coverage
GALEN safe and effective in relapsed and refractory follicular lymphoma
LUGANO, SWITZERLAND – Obinutuzumab, a follow-on to rituximab, appeared to be especially useful in combination with lenalidomide among patients who...